SOP for Qualification of QC Analysts

In short: This illustrative SOP describes how a pharmaceutical QC laboratory can document an analyst’s competence for assigned methods. Qualification should be based on the person’s role, training and method-specific evidence, with authorized review; the sample counts, RSD limits and requalification intervals in the imported template are local criteria that require confirmation.

Objective

Provide a framework for training, assessing, authorizing and periodically reviewing the competence of Quality Control analysts for the methods assigned to them. This is an example SOP for adaptation and approval under a site quality system; it is not a controlled or approved procedure for any particular facility.

Scope

This template applies to QC analysts performing pharmaceutical laboratory work. Define the methods, instruments, products, responsibilities and required level of oversight for each analyst according to the laboratory’s approved quality system.

Responsibilities

Example in-house criterion (not a pharmacopoeial requirement): The QC manager or designated supervisor coordinates method-specific training and assessment; the Quality Unit approves the local authorization and oversight process. Adapt titles and approval responsibilities to the site organization.

Procedure

1. Define the competence needed

For each role, document the methods and activities the analyst may perform, the required knowledge and practical skills, the training needed, and how competence will be assessed. WHO’s current guidance for pharmaceutical QC laboratories says competence requirements for each function should be documented and that procedures and criteria should be used to select and assess personnel. It also calls for records of education, qualification, training and experience (WHO TRS 1052, Annex 4, §§5.1–5.2, 2024).

For personnel within its scope, 21 CFR 211.25 (current eCFR, accessed 16 October 2026) requires education, training and experience sufficient for assigned functions and training in the operations the employee performs and applicable CGMP. EU GMP Part I, Chapter 2, §§2.10–2.11 (2014) calls for training of personnel who work in control laboratories, training appropriate to assigned duties, continuing training, periodic assessment of its practical effectiveness, and training records. Neither source gives one analyst-qualification schedule or one acceptance limit for all methods.

2. Train the analyst

Provide documented training on the assigned method, instrument, relevant procedures, records, data handling and laboratory practices before the analyst performs work independently. Assess the practical effectiveness of continuing training as required by the applicable quality system. Record the training topic, date, trainer, analyst and assessment outcome.

Example in-house criterion (not a pharmacopoeial requirement): Use a training checklist for each method and instrument, followed by a supervised practical exercise before the analyst is authorized to perform that work without direct supervision.

3. Assess method-specific performance

Prepare an approved assessment plan before testing. It should identify the method and specification, sample type, applicable acceptance criteria, required data and records, reviewer, and decision process. The plan should test the competencies relevant to the assigned method, such as accurate execution, precision where appropriate, following the written method, recording data contemporaneously, and handling atypical results.

Example in-house criterion (not a pharmacopoeial requirement): A supervisor may provide a coded sample with documented identity and an approved reference result, then compare the analyst’s work and records against the method-specific assessment plan. The original template uses the sample code AQ-YY-001; sites may adapt or replace this local coding convention.

The imported template proposes these method-specific exercise counts and limits. They are reproduced here for Admin review only and are not universal GMP or pharmacopoeial acceptance criteria:

Example in-house criterion (not a pharmacopoeial requirement): Use acceptance limits from the approved method, product specification or a separately justified qualification plan as applicable. WHO guidance says test results should be reviewed and approved or rejected by designated qualified personnel according to the laboratory’s competency list or matrix (WHO TRS 1052, Annex 4, §6.56, 2024).

4. Decide authorization and address gaps

Example in-house criterion (not a pharmacopoeial requirement): Document whether the analyst is authorized for the assessed method, the scope of authorization, required supervision, and any limitations. If the assessment identifies a gap, document follow-up training and re-assessment before changing authorization; keep the supporting data and reviewer’s assessment with the qualification record.

Example in-house criterion (not a pharmacopoeial requirement): Maintain an analyst competency matrix and qualification card that identify approved methods, instruments, assessment dates, reviewers and current authorization status. Issue a certificate only if the site’s controlled process uses one; a certificate does not replace the underlying assessment records.

5. Review competence over time

WHO guidance calls for regular monitoring of personnel competence but does not set a universal calendar interval (WHO TRS 1052, Annex 4, §4.17, 2024). EU GMP Chapter 2 requires continuing training and periodic assessment of its practical effectiveness. Example in-house criterion (not a pharmacopoeial requirement): Review competence when training, method or instrument changes, performance concerns, or assigned duties make reassessment appropriate under the approved site process.

The imported procedure contains two different calendar intervals: one passage proposes requalification of experienced analysts on critical tests every three years, while another says all analysts should be requalified every two years or as required. The reviewed official sources do not prescribe either interval as a universal rule.

6. Maintain records

Maintain the training, qualification, assessment, review and authorization records under the applicable retention schedule. WHO TRS 1052, Annex 4, §3.20 (2024) recommends retaining original observations and quality or technical records for no less than five years, subject to national law or contract. For batch-associated production, control or distribution records, 21 CFR 211.180(a) requires at least one year after the respective batch’s expiry where applicable; EU GMP Part I, Chapter 4, §4.11 (January 2011) requires batch documentation for one year after expiry or at least five years after QP certification, whichever is longer. Apply any longer local-law, contractual or marketing-authorisation period.

For related reading, see personnel good practices for pharmaceutical QC laboratories, the analyst qualification SOP, and the employee training SOP.

Frequently asked questions

Does GMP require the same qualification test for every analyst?

No. The sources reviewed focus on competence for assigned functions and the methods an analyst performs. Define the scope and evidence needed for each method and role.

Are the listed RSD limits regulatory limits for analyst qualification?

The official sources cited here do not establish the imported RSD matrix as universal analyst-qualification criteria. Confirm each limit against the specific method, product specification and approved local plan.

Must analysts be requalified every two or three years?

The imported template contains both intervals. EU GMP calls for continuing training and periodic assessment of practical effectiveness, and WHO guidance calls for regular competence monitoring; neither gives a universal two- or three-year interval. Resolve and approve the site’s interval and reassessment triggers.

How long should qualification records be retained?

WHO TRS 1052, Annex 4, §3.20 recommends a minimum of five years for quality and technical records, subject to national law or contract. For batch-associated records, also apply the one-year-after-expiry rule in EU GMP Part I, Chapter 4, §4.11 and 21 CFR 211.180(a), where applicable, or any longer requirement.

References

• World Health Organization. WHO Good Practices for Pharmaceutical Quality Control Laboratories, WHO Technical Report Series No. 1052, Annex 4, §§3.20, 4.17, 5.1–5.2, 6.56 (2024). Official WHO text.
• European Commission. EudraLex Volume 4, EU GMP Guide, Part I, Chapter 2: Personnel, §§2.1, 2.3, 2.10–2.11 (2014; effective 16 February 2014). Official chapter.
• U.S. Electronic Code of Federal Regulations, current as of 14 October 2026: 21 CFR §211.25, Personnel qualifications. Official eCFR text.
• European Commission. EudraLex Volume 4, EU GMP Guide, Part I, Chapter 4: Documentation, §4.11 (January 2011). Official chapter.
• U.S. Electronic Code of Federal Regulations, current as of 14 October 2026: 21 CFR §211.180(a), General requirements for records. Official eCFR text.